Pharmaceuticals & Biotech/Lifesciences

FNArena Windows (Sectors)

Introduction to FNArena Windows

FNArena Windows offers subscribers the option to investigate ASX-listed stocks against their peers. FNArena developed its own sector methodology which in our view overcomes many flaws and disadvantages connected with GICS sectors. Our system starts with three broad sector labels: COMMODITIES, FINANCIAL SERVICES and INDUSTRIALS. From here onwards subscribers can explore further through gradually narrowing branches. This is not investment advice, but simply another window on the Australian Stock Exchange to provide better insight and to assist FNArena subscribers while conducting their own market analysis.

Latest Stories

Janus Henderson’s Andy Acker explains why small and mid-cap biotechs have seriously underperformed, and why a strong recovery could be expected

Sep 14 2021

Timing will be everything for CSL, which is endeavouring to keep up the flow of plasma while collections activity remains beset by the pandemic

Aug 19 2021


ASX CODE COMPANY NAME LAST PRICE 52WK HIGH 52WK LOW P/E CONSENSUS TARGET
ANP ANTISENSE THERAPEUTICS LIMITED $0.20 $0.27 $0.09

$0.45

CSL CSL LIMITED $312.41 $320.42 $242.00 47.9

$305.317

MDC MEDLAB CLINICAL LIMITED $0.15 $0.42 $0.14

$0.29

MYX MAYNE PHARMA GROUP LIMITED $0.28 $0.59 $0.26

$0.307

PAR PARADIGM BIOPHARMACEUTICALS LIMITED $1.82 $3.19 $1.76

$1.68

PNV POLYNOVO LIMITED $1.96 $xx.xx $xx.xx xx.x xx.xx
Previous Stories
Flying High – Medicinal Marijuana In Australia

Jul 26 2021

Australia has the potential to become the international gold standard for production of medicinal marijuana and multiple ASX-listed companies are seeking to benefit


Wesfarmers On Drugs?

Jul 13 2021

Wesfarmers has flagged its planned expansion into the personal care, health and well-being sector with a bid for Australian Pharmaceutical Industries that has surprised brokers


Is CSL’s Plasma Recovery Now Priced In?

Jun 23 2021

Trends in plasma collections are improving for CSL but is the recovery being priced in?


CSL: Buy The Dip

Jun 22 2021

Michael Gable of Fairmont Equities suggests CSL is set for a short term share price dip, providing an attractive entry point


CSL To Retest Its High?

May 25 2021

Michael Gable of Fairmont Equities suggests that having retested its lows, CSL now could be set to retest its high


Treasure Chest: CSL Plasma At Turning Point?

May 05 2021

FNArena’s Treasure Chest reports on money making ideas from stockbrokers and other experts. As mobility across the US improves, attendance at CSL’s plasma collection centres is turning around, providing more optimism about the outlook


The War For Drugs

Apr 07 2021

With their mind blowing medical potential, are hallucinogens the next ASX ‘pot stock’ equivalent?


Rudi’s View: CSL, The Answers

Apr 01 2021

In Weekly Insights this week: -CSL, The Answers-Research To Download CSL, The Answers By Rudi Filapek-Vandyck, Editor FNArena Since listing…


Is CSL Ready To Turn Around?

Mar 16 2021

A slump in plasma collections as a result of pandemic-induced lockdowns has put the share price of CSL under pressure. With a vaccine roll-out is it time to buy?


Opthea Targets Vision Improvement

Nov 18 2020

Biopharmaceutical company Opthea is poised to undertake two phase-3 trials for its treatment to improve vision for those affected by macular degeneration